L1PA Stock Overview
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Lee's Pharmaceutical Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.15 |
| 52 Week High | HK$0.18 |
| 52 Week Low | HK$0.12 |
| Beta | 0.75 |
| 1 Month Change | 10.95% |
| 3 Month Change | 7.80% |
| 1 Year Change | 13.43% |
| 3 Year Change | -29.63% |
| 5 Year Change | n/a |
| Change since IPO | -70.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| L1PA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.8% | -6.6% | 0.8% |
| 1Y | 13.4% | -27.7% | 14.6% |
Return vs Industry: L1PA exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: L1PA underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| L1PA volatility | |
|---|---|
| L1PA Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: L1PA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: L1PA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,022 | n/a | www.leespharm.com |
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, such as cardiovascular, woman’s health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments.
Lee's Pharmaceutical Holdings Limited Fundamentals Summary
| L1PA fundamental statistics | |
|---|---|
| Market cap | €93.94m |
| Earnings (TTM) | €10.69m |
| Revenue (TTM) | €160.68m |
8.8x
P/E Ratio0.6x
P/S RatioIs L1PA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L1PA income statement (TTM) | |
|---|---|
| Revenue | HK$1.40b |
| Cost of Revenue | HK$646.61m |
| Gross Profit | HK$753.36m |
| Other Expenses | HK$660.26m |
| Earnings | HK$93.10m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 53.81% |
| Net Profit Margin | 6.65% |
| Debt/Equity Ratio | 13.8% |
How did L1PA perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield28%
Payout RatioDoes L1PA pay a reliable dividends?
See L1PA dividend history and benchmarks| Lee's Pharmaceutical Holdings dividend dates | |
|---|---|
| Ex Dividend Date | May 28 2025 |
| Dividend Pay Date | Jun 16 2025 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 29 days |
Does L1PA pay a reliable dividends?
See L1PA dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 02:39 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lee's Pharmaceutical Holdings Limited is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Cheng | 3V Capital Limited |
| Yue-Kwong Lui | BOCOM International Securities Limited |
| Chu Wang | Citigroup Inc |